[1] |
Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013[J]. Lancet,2015,386(10003):1546-1555.
|
[2] |
Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol,2017,67(2):370-398.
|
[3] |
中华医学会感染病学分会中华医学会肝病学分会. 慢性乙型肝炎防治指南(2015年版)[J]. 实用肝脏病杂志,2016,19(3):389-400.
|
[4] |
Giles M, Visvanathan K, Lewin S, et al. Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B[J]. Gut,2015,64(11):1810-1815.
|
[5] |
Tang L, Covert E, Wilson E, et al. Chronic hepatitis B infection: A review[J]. JAMA,2018,319(17):1802-1813.
|
[6] |
Pan CQ, Zou HB, Chen Y, et al. Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants[J]. Clin Gastroenterol Hepatol,2013,11(10):1349-1355.
|
[7] |
杨敏, 刘映霞. 慢性乙型肝炎母婴传播的影响因素新进展[J/CD]. 中华实验和临床感染病杂志(电子版),2016,10(3):265-268.
|
[8] |
Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load[J]. N Engl J Med,2016,374(24):2324-2334.
|
[9] |
Sellier PO, Maylin S, Bercot B, et al. Prospective interventional study of tenofovir in pregnancy to prevent vertical transmission of hepatitis B in highly viremic women[J]. Eur J Gastroenterol Hepatol,2017,29(3):259-263.
|
[10] |
Marcellin P, Zoulim F, Hezode C, et al. Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3-year, prospective, real-world study in France[J]. Dig Dis Sci,2016,61(10):3072-3083.
|
[11] |
Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology,2016,63(1):261-283.
|
[12] |
Pan CQ, Han GR, Jiang HX, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B[J]. Clin Gastroenterol Hepatol,2012,10(5):520-526.
|
[13] |
Chen T, Wang J, Feng Y, et al. Dynamic changes of HBV markers and HBV DNA load in infants born to HBsAg(+) mothers: can positivity of HBsAg or HBV DNA at birth be an indicator for HBV infection of infants?[J]. BMC Infect Dis,2013,13:524-531.
|
[14] |
Liu CP, Zeng YL, Zhou M, et al. Factors associated with mother-to-child transmission of hepatitis B virus despite immunoprophylaxis[J]. Intern Med,2015,54(7):711-716.
|
[15] |
Shiha G, Ibrahim A, Helmy A, et al. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update[J]. Hepatol Int,2017,11(1):1-30.
|
[16] |
Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology,2016,63(1):261-283.
|
[17] |
中华医学会妇产科学分会产科学组. 乙型肝炎病毒母婴传播预防临床指南(第1版)[J]. 中华妇产科杂志,2013,48(2):151-154.
|
[18] |
Xiao F, Lan A, Mo W. Breastfeeding from mothers carrying HBV would not increase the risk of HBV infection in infants after proper immunoprophylaxis[J]. Minerva Pediatr,2017. [Epub ahead of print].
|
[19] |
Chen X, Chen J, Wen J, et al. Breastfeeding is not a risk factor for mother-to-child transmission of hepatitis B virus[J]. PLoS One,2013,8(1):e55303.
|
[20] |
Sokal EM, Paganelli M, Wirth S, et al. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition[J]. J Hepatol,2013,59(4):814-829.
|
[21] |
Kim HY, Choi JY, Park CH, et al. Outcome after discontinuing antiviral agents during pregnancy in women infected with hepatitis B virus[J]. J Clin Virol,2013,56(4):299-305.
|
[22] |
盛秋菊, 丁洋, 李佰君, 等. HBV感染免疫耐受期孕妇应用替比夫定阻断母婴传播有效性及停药安全性的研究[J]. 中华肝脏病杂志,2016,24(4):258-264.
|
[23] |
Liu Y, Wang M, Yao S, et al. Efficacy and safety of telbivudine in different trimesters of pregnancy with high viremia for interrupting perinatal transmission of hepatitis B virus[J]. Hepatol Res,2016,46(3):E181-E188.
|
[24] |
Nguyen V, Levy MT. Editorial: Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth and the risk of post-partum flare, authors’ reply[J]. Aliment Pharmacol Ther,2014,40(1):116.
|
[25] |
陈蓉, 刘寿荣, 张素英, 等. 替比夫定阻断乙型肝炎病毒母婴垂直传播及分娩后停药时间对母亲安全性的影响[J]. 中华肝脏病杂志,2012,20(9):703-704.
|